Literature DB >> 1445568

Nucleotide sequence analysis and serologic characterization of the Mycobacterium intracellulare homologue of the Mycobacterium tuberculosis 19 kDa antigen.

J Nair1, D A Rouse, S L Morris.   

Abstract

Disseminated Mycobacterium avium/Mycobacterium intracellulare complex (MAC) disease is a frequent complication in patients with the acquired immune deficiency syndrome (AIDS). In this report, we present the nucleotide sequence of the M. intracellulare MI22 gene. Computer sequence comparisons reveal that the MI22 gene, which encodes a serologically active protein, has 78% DNA sequence identity and 77% protein sequence identity with the seroreactive 19 kDa Mycobacterium tuberculosis lipoprotein antigen. Southern blot hybridizations indicate that an MI22 gene probe binds similar-sized restriction fragments in M. tuberculosis and M. intracellular genomic DNA. In addition, immunoblot analyses demonstrate that MI22 is recognized by sera from tuberculosis patients. These data further support the existence of 19 kDa MAC and M. tuberculosis protein homologues. Phase partitioning experiments and the presence of a consensus lipid modification site in the deduced MI22 protein sequence strongly suggest that M122 is also a lipoprotein. Comparative analyses of these mycobacterial antigenic homologues may provide the basis for the design of species-specific diagnostic reagents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1445568     DOI: 10.1111/j.1365-2958.1992.tb00863.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  14 in total

1.  Functional domains present in the mycobacterial hemagglutinin, HBHA.

Authors:  G Delogu; M J Brennan
Journal:  J Bacteriol       Date:  1999-12       Impact factor: 3.490

2.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1992-09-25       Impact factor: 16.971

3.  A comparison of the T cell delayed-type hypersensitivity epitopes of the 19-kD antigens from Mycobacterium tuberculosis and Myco. intracellulare using overlapping synthetic peptides.

Authors:  J C Mackall; G H Bai; D A Rouse; G R Armoa; F Chuidian; J Nair; S L Morris
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

4.  Molecular and immunological analyses of the Mycobacterium avium homolog of the immunodominant Mycobacterium leprae 35-kilodalton protein.

Authors:  J A Triccas; N Winter; P W Roche; A Gilpin; K E Kendrick; W J Britton
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

5.  Secretion of the mycobacterial 19-kilodalton protein by Escherichia coli, a novel method for the purification of recombinant mycobacterial antigens.

Authors:  R G Hewinson; D P Harris; A Whelan; W P Russell
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

Review 6.  Lipoproteins of gram-positive bacteria.

Authors:  I C Sutcliffe; R R Russell
Journal:  J Bacteriol       Date:  1995-03       Impact factor: 3.490

Review 7.  Diagnosis of tuberculosis: available technologies, limitations, and possibilities.

Authors:  Sanjay K Garg; R P Tiwari; Dileep Tiwari; Rupinder Singh; Dolly Malhotra; V K Ramnani; G B K S Prasad; Ramesh Chandra; M Fraziano; V Colizzi; Prakash S Bisen
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

8.  Molecular mechanisms of isoniazid resistance in Mycobacterium tuberculosis and Mycobacterium bovis.

Authors:  D A Rouse; S L Morris
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

9.  Nucleotide sequence analysis and serologic characterization of a 27-kilodalton Mycobacterium intracellulare lipoprotein.

Authors:  J Nair; D A Rouse; S L Morris
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

10.  Expression of the Mycobacterium tuberculosis 19-kilodalton antigen in Mycobacterium smegmatis: immunological analysis and evidence of glycosylation.

Authors:  T Garbe; D Harris; M Vordermeier; R Lathigra; J Ivanyi; D Young
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.